R Contains Benzene Ring Patents (Class 514/617)
-
Patent number: 8748477Abstract: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, and compositions thereof, which also has fragrance properties, may be used commercially for its insect repellent properties.Type: GrantFiled: November 3, 2005Date of Patent: June 10, 2014Assignee: E I du Pont de Nemours and CompanyInventor: Mark A. Scialdone
-
Publication number: 20140142156Abstract: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial.Type: ApplicationFiled: December 12, 2013Publication date: May 22, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Helen E. BLACKWELL, Christine E. McINNIS
-
Patent number: 8728506Abstract: Disclosed is a pest repellent that has excellent heat resistance and solvent resistance, that can be kneaded into a resin molded article or a synthetic fiber, and that has excellent durability and persistence for which a pest repellent effect is sustained for a long period even when it is used for a long period or washed. A durable pest repellent that has both high heat resistance and persistence has been accomplished by supporting on a specific layered silicate a pest repellent chemical containing as an essential component at least one selected from N,N-diethyl-m-toluamide, 1-piperidinecarboxylic acid-2-(2-hydroxyethyl)-1-methylpropyl ester, and N,N-diethyl-m-toluamide and 1-piperidinecarboxylic acid-2-(2-hydroxyethyl)-1-methylpropyl ester.Type: GrantFiled: September 16, 2010Date of Patent: May 20, 2014Assignee: Toagosei Co., Ltd.Inventor: Yasuharu Ono
-
Publication number: 20140134283Abstract: The invention discloses compositions, including nutritional products and dietary supplements, comprising aegeline, which is a compound that occurs naturally in the Bael plant. The invention also describes methods comprising the administration of aegeline to mammals. The methods result in increased mental stamina, focus, and energy level, improved mood, increased thermogenesis, increased libido, and anabolic effects and increased strength output and/or muscle mass. These effects can improve cognition, influence body composition, promote weight loss, and/or promote fitness and well-being. A novel method for the synthesis of aegeline is also provided.Type: ApplicationFiled: March 13, 2013Publication date: May 15, 2014Applicant: USPlabs. LLCInventors: Jacobo Edward Geissler, Jiang Zhou, Yang Jiang, Li Zhou
-
Patent number: 8716337Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.Type: GrantFiled: April 12, 2012Date of Patent: May 6, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
-
Patent number: 8716343Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.Type: GrantFiled: April 24, 2012Date of Patent: May 6, 2014Assignee: Regents of the University of MinnesotaInventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
-
Patent number: 8716527Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2- substituted-p-quinone derivatives as disclosed herein.Type: GrantFiled: March 4, 2009Date of Patent: May 6, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell
-
Publication number: 20140113898Abstract: The invention relates to bisarylsulfone and dialkylarylsulfone compounds (e.g., compounds according to any of Formulas (I)-(IX) or compounds (1)-(227) of Tables 4 and 5) useful in treating conditions associated with calcium channel function, and particularly conditions associated with N-type calcium channel activity. The invention also relates to pharmaceutical compositions that include these bisarylsulfone compounds, as well methods for the treatment of conditions such as cardiovascular disease, epilepsy, cancer and pain.Type: ApplicationFiled: November 4, 2011Publication date: April 24, 2014Applicant: Zalicus Pharmaceuticals Ltd.Inventors: Hassan A. Pajouhesh, Richard Holland, Yuanxi Zhou, Yongbao Zhu, Michael Edward Grimwood, Navjot Chahal
-
Publication number: 20140107134Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.Type: ApplicationFiled: September 27, 2013Publication date: April 17, 2014Applicant: Synta Pharmaceuticals Corp.Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
-
Patent number: 8697911Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: June 29, 2011Date of Patent: April 15, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Brian Nicholas Cook, Jennifer A. Kowalski, Xiang Li, Daniel Richard Marshall, Sabine Schlyer, Robert Sibley, Lana Louise Smith-Keenan, Fariba Soleymanzadeh, Ronald John Sorcek, Erick Richard Roush Young, Yunlong Zhang
-
Patent number: 8691845Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: July 30, 2012Date of Patent: April 8, 2014Assignee: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8691839Abstract: The present application relates generally to amino tetraline derivative compounds and methods of use, specifically, embodiments including compounds of formula (I) described herein, pharmaceutically acceptable salts and solvates. More specifically, this application relates to amino tetraline derivative compounds and uses of such compounds producing medicaments for the treatment of various disease and conditions including movement disorders and disorders of the central nervous system.Type: GrantFiled: August 15, 2013Date of Patent: April 8, 2014Inventors: Peter Gmeiner, Miriam Ruberg, Harald Huebner
-
Patent number: 8685936Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.Type: GrantFiled: March 12, 2010Date of Patent: April 1, 2014Assignee: Apogee Biotechnology CorporationInventors: Charles D. Smith, Yan Zhuang, Lynn W. Maines
-
Patent number: 8686045Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.Type: GrantFiled: June 8, 2006Date of Patent: April 1, 2014Assignees: The University of North Carolina at Chapel Hill, The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Frank M. Longo, Stephen M. Massa
-
Patent number: 8686044Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclie. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.Type: GrantFiled: January 28, 2011Date of Patent: April 1, 2014Assignee: Mitsui Chemicals Agro, Inc.Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
-
Patent number: 8686046Abstract: Amidine analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumor cells.Type: GrantFiled: October 2, 2010Date of Patent: April 1, 2014Assignee: University of Virginia Patent FoundationInventors: Kevin R. Lynch, Timothy L. Macdonald, Yugesh Kharel, Thomas P. Mathews, Brian R. Wamhoff
-
Publication number: 20140088105Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.Type: ApplicationFiled: November 22, 2013Publication date: March 27, 2014Applicant: NOVARTIS AGInventors: David Beattie, Andrew James Culshaw, Lisa Rooney, Emily Stanley
-
Publication number: 20140088157Abstract: Provided are an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I): or a salt thereof as an active ingredient, and a method for controlling endoparasites, comprising orally or parenterally administering the endoparasite control agent.Type: ApplicationFiled: March 1, 2012Publication date: March 27, 2014Applicants: NIHON NOHYAKU CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kiyoshi Kita, Akiyuki Suwa
-
Patent number: 8680157Abstract: The invention relates to the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to assay systems allowing to test LSD1 inhibitors for their ability to inhibit LSD1 function.Type: GrantFiled: February 16, 2006Date of Patent: March 25, 2014Assignee: Universitaetsklinikum FreiburgInventors: Roland Schuele, Eric Metzger
-
Patent number: 8680150Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.Type: GrantFiled: May 6, 2010Date of Patent: March 25, 2014Assignee: Ligand Pharmaceuticals, Inc.Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Jason C. Pickens, Yixing Shen, Catalina Cuervo, Lino J. Valdez, Jillian Basinger, Virgina H. Grant
-
Patent number: 8669286Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.Type: GrantFiled: September 26, 2012Date of Patent: March 11, 2014Assignee: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
-
Publication number: 20140057946Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels.Type: ApplicationFiled: February 13, 2013Publication date: February 27, 2014Applicant: GtxInventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss
-
Publication number: 20140057953Abstract: The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 2 (l7beta-HSD2) inhibitors of formula (I), their production and use, notably for the treatment and prophylaxis of sex steroid deficient diseases like osteoporosis in men and women.Type: ApplicationFiled: March 2, 2012Publication date: February 27, 2014Inventors: Rolf Hartmann, Sandrine Marchais-Oberwinkler, Kuiying Xu, Ruth Werth
-
Publication number: 20140057985Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels.Type: ApplicationFiled: December 13, 2012Publication date: February 27, 2014Applicant: GtxInventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss
-
Publication number: 20140051693Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.Type: ApplicationFiled: October 22, 2013Publication date: February 20, 2014Inventors: Bruce Roseman, Gilla Kaplan
-
Publication number: 20140051655Abstract: Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.Type: ApplicationFiled: March 5, 2013Publication date: February 20, 2014Applicant: Elan Pharmaceuticals, Inc.Inventor: Elan Pharmaceuticals, Inc.
-
Publication number: 20140045774Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.Type: ApplicationFiled: June 11, 2013Publication date: February 13, 2014Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Susan Perrine, Douglas Faller
-
Patent number: 8648110Abstract: Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.Type: GrantFiled: April 22, 2011Date of Patent: February 11, 2014Assignee: Dompe Pha.R.Ma S.p.A.Inventors: Alessio Moriconi, Marcello Allegretti, Maria Candida Cesta, Riccardo Bertini, Cinzia Bizzarri, Francesco Colotta
-
Publication number: 20140038974Abstract: The invention provides compositions and methods for whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidine, guanfacine or fadolmidine.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: Eye Therapies, LLCInventor: Gerald Horn
-
Publication number: 20140039060Abstract: The invention relates to compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.Type: ApplicationFiled: October 9, 2013Publication date: February 6, 2014Inventor: Eliahu Kaplan
-
Patent number: 8642576Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.Type: GrantFiled: August 29, 2012Date of Patent: February 4, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
-
Patent number: 8642656Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.Type: GrantFiled: September 28, 2012Date of Patent: February 4, 2014Assignee: Regents of the University of MinnesotaInventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
-
Publication number: 20140031341Abstract: An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.Type: ApplicationFiled: December 19, 2011Publication date: January 30, 2014Applicants: UNIVERSITAT MUNSTER, GALDERMA RESEARCH & DEVELOPMENTInventors: Jerome Aubert, Martin Steinhoff
-
Publication number: 20140031395Abstract: The present invention relates to compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also inflammatory diseases.Type: ApplicationFiled: February 2, 2012Publication date: January 30, 2014Applicant: Bionomics LimitedInventors: Andrew Harvey, Audrey Fluck, Bruno Giethlen, Dharam Paul, Laurent Schaeffer
-
Patent number: 8637576Abstract: Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are defined as provided herein.Type: GrantFiled: October 20, 2009Date of Patent: January 28, 2014Assignee: Amgen Inc.Inventors: Jay P. Powers, Michael R. Degraffenreid, Xiao He, Lisa D. Julian, Dustin L. McMinn, Daqing Sun, Yosup Rew, Xuelei Yan
-
Patent number: 8637706Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.Type: GrantFiled: January 31, 2012Date of Patent: January 28, 2014Assignee: Gtx, Inc.Inventors: James T. Dalton, Christina Barrett, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
-
Patent number: 8618086Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.Type: GrantFiled: June 13, 2008Date of Patent: December 31, 2013Assignee: Duke UniversityInventors: Mitchell Anthony deLong, John McMillan McIver, Robert Scott Youngquist
-
Publication number: 20130338178Abstract: Agents and methods of inhibiting or improving the growth of viruses are provided.Type: ApplicationFiled: February 2, 2012Publication date: December 19, 2013Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Thomas Shenk, Emre Koyuncu, Ileana Cristea
-
Publication number: 20130330282Abstract: Spray compositions are formulated with powders (e.g. corn starch) which improve skin feel, and also have a hydrophobically modified oxide additive (e.g. modified silica) to reduce the incidence of can/bottle clogging and sedimentation caused by the powder. The oxide is a mixed hydrophobic/hydrophilic oxide such as hydrophobicly modified fumed silica (e.g. silica dimethyl silylate). In one embodiment DEET can be delivered by such formulations.Type: ApplicationFiled: June 8, 2012Publication date: December 12, 2013Inventor: John S. Trent
-
Publication number: 20130331392Abstract: The invention provides cycloalkyl guanidine compounds that inhibit F1F0-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.Type: ApplicationFiled: December 8, 2011Publication date: December 12, 2013Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
-
Patent number: 8604083Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: July 2, 2007Date of Patent: December 10, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. Von Borstel, Kirvin L. Hodge, Michael K. Bamat, Stephen D. Wolpe
-
Patent number: 8592486Abstract: The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.Type: GrantFiled: May 14, 2012Date of Patent: November 26, 2013Assignee: Synta Pharmaceuticals Corp.Inventors: Lijun Sun, Shoujun Chen, Zhi-Qiang Xia, Jun Jiang, Yu Xie, Junyi Zhang
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Patent number: 8586603Abstract: The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system.Type: GrantFiled: December 20, 2010Date of Patent: November 19, 2013Inventors: Peter Gmeiner, Miriam Ruberg, Harald Hüebner
-
Patent number: 8581005Abstract: The present invention relates to inhibitors of mitochondria-associated, granulocyte-macrophage colony stimulating factor signaling molecule (Magmas), and related compositions and uses thereof.Type: GrantFiled: March 16, 2010Date of Patent: November 12, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Paul Jubinsky, Bhaskar C. Das, Mary K. Short
-
Publication number: 20130296383Abstract: The present invention relates to decahydro-1,4-methanonaphthalen carboxamide derivatives of formula (Ia) or (Ib); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.Type: ApplicationFiled: November 14, 2011Publication date: November 7, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Jörg Greul, Jürgen Benting, Peter Dahmen, Ulrike Wachendorff-Neumann
-
Publication number: 20130276352Abstract: A termite bait includes a plurality of cellulosic food material pieces palatable to termites embedded within a water resistant polyurethane foam matrix. Another termite bait includes a plurality of cellulosic food material pieces embedded within a water-absorbent polyurethane foam matrix. Yet another termite bait includes at least one cellulosic food material piece encapsulated within a water resistant polyurethane foam coating. Such termite baits can be used alone or in a monitoring device or other termite control device. Another termite control device includes a container, a cellulosic food material within the container and a water resistant polyurethane foam positioned to separate the food material from its environment. The container can contain a termite bait as described above or can include a chamber containing a cellulosic food material and at least one pocket containing a polyurethane foam barrier to reduce intrusion of water through the pocket to the food material.Type: ApplicationFiled: March 15, 2013Publication date: October 24, 2013Inventor: Dow AgroSciences LLC
-
Publication number: 20130281294Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.Type: ApplicationFiled: June 17, 2013Publication date: October 24, 2013Inventors: HUAZHANG HUANG, Ratnakar Asolkar
-
Publication number: 20130281394Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Patent number: 8563615Abstract: The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.Type: GrantFiled: November 1, 2010Date of Patent: October 22, 2013Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc., Massachusetts General HospitalInventors: Li-Huei Tsai, Ji-Song Guan, Stephen J. Haggarty, Edward Holson, Florence Wagner, Johannes Graeff